PDGFRA and neoplasm: Anlotinib is a novel oral multitarget TKI targeting VEGFR‐2 and VEGFR−3, FGFR1‐4, PDGFR‐α, PDGFR‐β, and c‐Kit, thereby inhibiting tumor growth and angiogenesis.21